BDBM47165 US8957103, C1::US9364459, I

SMILES COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCCO)c2ccccc12

InChI Key InChIKey=IFUKBECSYNPLCY-UHFFFAOYSA-N

Data  9 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 9 hits for monomerid = 47165   

TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johannes Gutenberg—Universitat Mainz

US Patent
LigandPNGBDBM47165(US8957103, C1 | US9364459, I)
Affinity DataIC50:  920nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Johannes Gutenberg—Universitat Mainz

US Patent
LigandPNGBDBM47165(US8957103, C1 | US9364459, I)
Affinity DataIC50:  556nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johannes Gutenberg—Universitat Mainz

US Patent
LigandPNGBDBM47165(US8957103, C1 | US9364459, I)
Affinity DataIC50:  2.25E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johannes Gutenberg—Universitat Mainz

US Patent
LigandPNGBDBM47165(US8957103, C1 | US9364459, I)
Affinity DataIC50:  153nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johannes Gutenberg—Universitat Mainz

US Patent
LigandPNGBDBM47165(US8957103, C1 | US9364459, I)
Affinity DataIC50:  2nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johannes Gutenberg—Universitat Mainz

US Patent
LigandPNGBDBM47165(US8957103, C1 | US9364459, I)
Affinity DataIC50:  3.39E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johannes Gutenberg—Universitat Mainz

US Patent
LigandPNGBDBM47165(US8957103, C1 | US9364459, I)
Affinity DataIC50:  920nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Johannes Gutenberg—Universitat Mainz

US Patent
LigandPNGBDBM47165(US8957103, C1 | US9364459, I)
Affinity DataIC50:  556nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Johannes Gutenberg—Universitat Mainz

US Patent
LigandPNGBDBM47165(US8957103, C1 | US9364459, I)
Affinity DataIC50:  554nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
In DepthDetails US Patent